This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Mallinckrodt Hospital Products IP Limited, Bellerophon Bcm LLC, Ino Therapeutics Gmbh. Active years: 2014-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
6 out of 83 
3 out of 4 
2 out of 36 
Years Active: 2014-2023
Title: The Innovations of Martin D. Meglasson: A Pioneer in Nitric Oxide Delivery
Introduction
Martin D. Meglasson, an accomplished inventor based in Bloomsbury, NJ, holds an impressive portfolio of 11 patents. His significant contributions to the field of medical devices, particularly in nitric oxide therapy, have made a substantial impact on improving patient care.
Latest Patents
Among his latest innovations is the patent for a "Cannula for Minimizing Dilution of Dosing During Nitric Oxide Delivery." This invention addresses the challenges associated with the accurate delivery of nitric oxide (NO) therapy. By reducing the dilution during inhalation, Meglasson's nasal cannulas enhance the precision of NO therapy. The design incorporates specific dimensions in the flow path and utilizes check valves in the delivery line to minimize retrograde flow. Furthermore, the materials used in these cannulas are engineered to limit oxygen diffusion through the walls, thereby optimizing the therapeutic effectiveness. The manufacturing process employs advanced molding techniques to produce the nosepiece of these innovative cannulas.
Career Highlights
Throughout his career, Martin has been associated with notable companies such as Mallinckrodt Hospital Products IP Limited and Bellerophon BCM LLC. His work in these organizations has focused on pushing the boundaries of medical technology, particularly in respiratory therapy and innovative delivery systems.
Collaborations
Martin has had the pleasure of collaborating with esteemed colleagues, including Craig Flanagan and Simon Freed. Their combined expertise has fostered a dynamic work environment that encourages creativity and innovation, further enhancing the development of effective therapeutic devices.
Conclusion
Martin D. Meglasson’s contributions to the field of nitric oxide therapy represent a significant advancement in medical technology. Through his inventive spirit and commitment to enhancing patient outcomes, Meglasson continues to be a key figure in the realm of medical innovations, paving the way for future advancements in respiratory care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile